Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $8.8 million.

  • Bicycle Therapeutics' Share-based Compensation fell 468.38% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.1 million, marking a year-over-year increase of 726.66%. This contributed to the annual value of $38.1 million for FY2024, which is 1725.53% up from last year.
  • Per Bicycle Therapeutics' latest filing, its Share-based Compensation stood at $8.8 million for Q3 2025, which was down 468.38% from $9.4 million recorded in Q2 2025.
  • Bicycle Therapeutics' Share-based Compensation's 5-year high stood at $10.3 million during Q4 2024, with a 5-year trough of $2.6 million in Q2 2021.
  • Its 5-year average for Share-based Compensation is $7.2 million, with a median of $8.2 million in 2023.
  • As far as peak fluctuations go, Bicycle Therapeutics' Share-based Compensation soared by 16689.35% in 2022, and later crashed by 1133.56% in 2023.
  • Over the past 5 years, Bicycle Therapeutics' Share-based Compensation (Quarter) stood at $3.0 million in 2021, then skyrocketed by 84.73% to $5.5 million in 2022, then surged by 41.01% to $7.8 million in 2023, then skyrocketed by 32.27% to $10.3 million in 2024, then decreased by 15.12% to $8.8 million in 2025.
  • Its Share-based Compensation stands at $8.8 million for Q3 2025, versus $9.4 million for Q2 2025 and $9.6 million for Q1 2025.